ProMECE-CytaBOM vs MACOP-B in Advanced Aggressive Non-Hodgkin's Lymphoma: Long Term Results of a Multicenter Study of the Italian Lymphoma Study Group (GISL)

References

• De Vila V. T., Jr., Hubbard S. M., Longo D. L. The chemotherapy of lymphoma: looking back, moving forward. Cancer Res. 1987; 47: 5810–5824
   PubMed Web of Science ®Google Scholar
• Armitage J. O. Treatment of non-Hodgkin's lymphomas. New Engl. J. Med. 1993; 328: 1023–1030
   PubMed Web of Science ®Google Scholar
• Skarin A. T., Canellos G., Rosenthal D. S., et al. Moderate dose methotrexate (m) combined with bleomycin (B), Adriamycin (A), cyclophosphamide (C). Oncovin (O) end dexamethasone (D), m-BACOD, in advanced diffuse histiocytic lymphomas (DHL). Proc. Am. Soc. Clin. Oncol. 1983; 2: 220, (Abs)
   Google Scholar
• Fisher R. I., DeVita V. T., Jr., Hubbard S. M., et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann. Intern. Med. 1983; 98: 304–309
   PubMed Web of Science ®Google Scholar
• Klimo P., Connors J. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann. Int. Med. 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Fisher R. I., DeVita V. T., Jr., Hubbard S. M., et al. Randomized trial of ProMACE-MOPP vs ProMACE-CytaBOM in previously untreated, advanced diffuse aggressive lymphomas. Proc. Am. Soc. Clin. Oncol. 1984; 3: 242, (Abs)
   Google Scholar
• Amadori S., Guglielmi C., Anselmo A. P., et al. Treatment of diffuse aggressive non-Hodgkin's lymphomas with an intensive multi-drug regimen including high-dose cytosine arabinoside (F-MACHOP). Semin. Oncol. 1985; 12(Suppl 3)218–222
   PubMedGoogle Scholar
• Boyd D. B., Coleman M., Papish S. W., et al. COPBLAM III: Infusional combination chemotherapy for diffuse large-cell lymphoma. J. Clin. Oncol. 1988; 6: 425–33
   PubMed Web of Science ®Google Scholar
• Coiffier B., Lepage E. Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in LNH-84 regimen. Blood 1989; 74: 558–564
   PubMed Web of Science ®Google Scholar
• Schein P. S., DeVita V. T., Jr., Hubbard S. M., et al. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann. Intern. Med. 1976; 85: 417–422
   PubMed Web of Science ®Google Scholar
• De Vita V. T., Jr., Hubbard S. M., Young R. C., et al. The role of chemotherapy in diffuse aggressive lymphomas. Semin. Haematol. 1988; 25(Suppl 2): 2–10
   Web of Science ®Google Scholar
• Federico M., Moretti G., Gobbi P. G., et al. ProMACE-CytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial. Leukemia 1991; 5(Suppl 1): 95–101
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Praga C., Intini C., Riva A., et al. International experience with epidoxorubicin in lymphomas. Proceedings of the 31st Congresso della Societa' Italiana di Ematologia, GenovaItaly, October, 4–8, 1987; II: 195, (Abs)
   Google Scholar
• Nie N. H., Hadlai, Hull C., Jenkins J. G., et al. SPSS (Statistical Package for the Social Sciences). McGraw-Hill, New York, NY 1979
   Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Peto R., Pike M. C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Cox D. R. Regression models and life-tables. J. R. Stat. Soc. [B] 1972; 34: 187–220
   Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Miller T. P., Dahlberg S., Weick J. K., et al. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group Study. J. Clin. Oncol. 1990; 8: 1951–1958
   PubMed Web of Science ®Google Scholar
• Vitolo U., Bertini M., Tarella C., et al. Macop-B treatment for advanced stage diffuse large cell lymphoma: a multicenter Italian study. Eur. J. Cancer Oncol. 1989; 25: 1441–1449
   PubMedGoogle Scholar
• Schneider A. M., Straus D. J., Schluger A. E., et al. Treatment result with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate and some high-grade non-Hodgkin's lymphomas. J. Clin. Oncol. 1990; 8: 94–102
   PubMed Web of Science ®Google Scholar
• Chisesi T., Santini G., Capnist G., et al. ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomized study in a multicentre cooperative study group (NHLCSG). Leukemia 1991; 5(Suppl 1)107–111
   PubMedGoogle Scholar
• Tura S., Zinzani P. L., Mazza P., et al. F-MACHOP vs MACOP-B in the treatment of high grade malignant non-Hodgkin's lymphomas. Blood 1991; 78(Suppl)109, (Abs)
   Google Scholar
• Meyer R. M., Quirt I. C., Skillings J. R., et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. New Engl. J. Med. 1993; 329: 1770–1776
   PubMed Web of Science ®Google Scholar
• Gordon L. I., Harrington D., Anderson J., et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N. Engl. J. Med. 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Cooper I. A., Wolf M. M., Robertson T. I., et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate grade non-Hodgkin's lymphoma. J. Clin. Oncol. 1994; 12: 769–778
   PubMed Web of Science ®Google Scholar
• Longo D. L., Duffey P. L. Management of aggressive histology lymphoma: an approach based on data from the National Cancer Institute. Hem./Onc. Annals. 1993; 1: 19–28
   Google Scholar
• Brugiatelli M., Federico M., Gobbi P. G., et al. Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial. Haematologica 1993; 78: 306–312
   PubMedGoogle Scholar
• Kwak L. W., Halpem Y., Olshen R. A., et al. Prognostic significance of actual dose intensity in diffuse large cell lymphoma: results of a tree-structured survival analysis. J. Clin. Oncol. 1990; 8: 756–765
   Google Scholar
• Epelbaum R., Faraggi D., Ben-Aire Y., et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 1990; 66: 1124–1129
   PubMed Web of Science ®Google Scholar
• Meyer R. M., Hryniuk W. M., Goodyear M. D. E. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 1991; 9: 339–347
   PubMed Web of Science ®Google Scholar